FDA Approves at-Home Starting Dose for Anti-Amyloid Therapy
The US Food and Drug Administration (FDA) approved a new subcutaneous starting dosage regimen for the amyloid β-directed antibody lecanemab-irmb, which would allow patients to begin the Alzheimer disease treatment at home.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.